"Immunocytokines market to exhibit profitable growth during the forecast period"
The global immunocytokines market is growing significantly. In recent years monoclonal antibodies are being utilized to treat a wide array of cancer-related diseases. These monoclonal antibodies are mainly mono-specific encompassing similar immune cells which are copies of a single parent cell and are concentrated towards a definite cellular target. These antibodies due to its customizable environment, it can be used to only treat the tumor cells ineffective of the normal ones in the living body. However, a huge number of immunocytokines in the pipeline, high prevalence with no or less medical efficiency in developing nations, less awareness, the high cost of treatment, inflexible government regulations towards cancer diagnosis are factors restraining the development of immunocytokines market globally.
"Tumors and cancer segment is expected to register higher growth in the developing nations by the end of 2029"
An increasing prevalence of cancer along with along with new technological assessment in genetic sequencing and target gene selection are factors driving the overall growth of the global immunocytokines market. Few human cytokines such as IL2 have been approved (Proleukin) for diseases such as metastatic renal cell carcinoma and metastatic melanoma. Chemotherapy and drugs are used to treat cancer. Various adverse side effects that comes with the medication has made the pharmaceutical organizations to concentrate on monoclonal antibodies along with immunocytokines. According to WHO, cancer is a leading cause of mortality on a global scale, in 2021, an estimated 9.8 million individuals passed away due to cancer. Majority of them were diagnosed with lung and breast cancer.
"Lung targeting site segment is expected to register higher growth in the developing nations by the end of 2029"
Advancement in antibody-based delivery of IL2 and cytotoxics has shown promising results in recent years. As per WHO in 2021, more than 2.08 million cases were registered due to lung cancer globally. More than 11 types of immunocytokines are still in pipeline (phase I/II). They have been developed against various, tumor-associated antigens such as epithelial, cell-adhesion molecule, carbonic anhydrase 9, fibroblast activation protein, epidermal growth factor receptor, fibronectin splice variants, and, tenascin splice variants. For instance, scientists from Philogen (Italy) have developed immunocytokines based on IL2, IL12, IL4, IL10 and TNF, which are presently being inspected in pre-clinical studies. Increasing geriatric population, government or private funding for cancer research, and changing lifestyles resulting in chronic disorders are factors driving the growth of immunocytokines market.
"Increasing prevalence of cervical cancer along with advanced diagnostic procedures is gaining traction in developing economies"
North America spearheaded the market in 2020 owing to the presence of top pharmaceutical and research organizations along with increasing incidences for breast and lung cancer in the U.S., as indicated by a report published by American Cancer Society, in 2021, more than 1.6 million new cancer cases were diagnosed and around 600,000 deaths were registered. In recent years, top biotechnology and pharmaceutical companies in the U.S. and Europe have started investing in monoclonal antibodies. The driving factors include, heavy investment in R&D, approval for antibody-based molecules (more than 70), huge number of medications in pipeline and advancement in conjugated cancer therapies worldwide.
"High prevalence of cancer, less availability of medications and treatment in the developing nations"
Major players in the immunocytokines market are Alkermes Plc, AstraZeneca Plc, CytImmune, Cytune Pharma, Altor Biosciences Corporation, Apeiron Biologics AG, Paladin Labs, Teva Pharmaceutical Industries Ltd., Valor Biotherapeutics, Targa Therapeutics Corporation, Immunomedics, Inc., ImmunGene, Inc., MolMed S.p.A., Merck KGaA, Nektar Therapeutics, Pfizer, Inc., F. Hoffmann-La Roche, Ltd. and others. These companies are employing growth strategies along with new approvals for medications related to cancer.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Immunocytokines market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Disease Indication
| |
Target Site
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
